- Home
- PHUN vs ANL Comparison
PHUN vs ANL Comparison
Compare PHUN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ANL
- Stock Information
- Founded
- PHUN 2009
- ANL 2004
- Country
- PHUN United States
- ANL Cayman Islands
- Employees
- PHUN N/A
- ANL N/A
- Industry
- PHUN EDP Services
- ANL
- Sector
- PHUN Technology
- ANL
- Exchange
- PHUN Nasdaq
- ANL Nasdaq
- Market Cap
- PHUN 55.9M
- ANL 61.8M
- IPO Year
- PHUN N/A
- ANL 2023
- Fundamental
- Price
- PHUN $2.92
- ANL $1.79
- Analyst Decision
- PHUN Buy
- ANL Hold
- Analyst Count
- PHUN 2
- ANL 1
- Target Price
- PHUN $7.75
- ANL N/A
- AVG Volume (30 Days)
- PHUN 250.9K
- ANL 11.3K
- Earning Date
- PHUN 11-06-2025
- ANL 10-21-2025
- Dividend Yield
- PHUN N/A
- ANL N/A
- EPS Growth
- PHUN N/A
- ANL N/A
- EPS
- PHUN N/A
- ANL N/A
- Revenue
- PHUN $2,400,000.00
- ANL N/A
- Revenue This Year
- PHUN N/A
- ANL N/A
- Revenue Next Year
- PHUN $72.40
- ANL N/A
- P/E Ratio
- PHUN N/A
- ANL N/A
- Revenue Growth
- PHUN N/A
- ANL N/A
- 52 Week Low
- PHUN $2.22
- ANL $1.10
- 52 Week High
- PHUN $14.60
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- PHUN 55.90
- ANL 55.55
- Support Level
- PHUN $2.70
- ANL $1.70
- Resistance Level
- PHUN $3.13
- ANL $1.82
- Average True Range (ATR)
- PHUN 0.15
- ANL 0.09
- MACD
- PHUN 0.02
- ANL -0.00
- Stochastic Oscillator
- PHUN 55.32
- ANL 60.33
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.